tbuckley/cabot-search huggingface dataset:
Fludarabine, Ara-C, Novantrone and Dexamethasone Plus Campath-1H for the Treatment of Patients with Chronic Lymphocytic Leukemia (CLL) and Adverse Clinical and Biologic Prognostic Features.
Authors: Francesca R. Mauro, Elena Giammartini, Maria S. De Propris, Giuseppe Gentile, Mauro Nanni, Emanuela M. Ghia, Irene Della Starza, Ilaria Del Giudice, Simona Santangelo, Marilisa Marinelli, Fulvia Brugnoletti, Clara Minotti, Vera Capria, Anna Guarini, Robert Foa
Journal: Blood (2006)
PUB136 Effect of PD-L1 Tumor Expression on Clinical Benefit of Personalized Dendritic Cell Based Vaccine in Patients with Non-Small Cell Lung Cancer
Authors: Natalia Khranovska, Oksana Skachkova, Roman Sydor, Mariia Inomistova, Vladimir Sovenko, Yurii Kondratsky
Journal: Journal of Thoracic Oncology (2017)
Combination of Nab-Rapamycin and Perifosine Induces Synergistic Cytotoxicity and Antitumor Activity Via Autophagy and Apoptosis in Multiple Myeloma (MM)
Authors: Diana Cirstea, Teru Hideshima, Samantha Pozzi, Sonia Vallet, Hiroshi Ikeda, Loredana Santo, Scott Rodig, Nileshwari Vaghela, Treeve Currie, Yutaka Okawa, Gaurav Chhetri, Chirayu G. Patel, Giulia Perrone, Gullu Gorgun, Elisabetta Calabrese, Voung Trieu, Neil Desai, Peter Sportelli, Nikhil C. Munshi, Kenneth C Anderson, Noopur Raje
Journal: Blood (2008)
5-Azacytidine Reduces Leukemic Burden in a Xenograft Model of Juvenile Myelomonocytic Leukemia
Authors: Christopher Felix Krombholz, Angelina Meier, Konrad Aumann, Silvia Fluhr, Matthias Kollek, Daniel B Lipka, Christoph Plass, Tania Witte, Charlotte Niemeyer, Miriam Erlacher, Christian Flotho
Journal: Blood (2015)
P1.05-027 Novel Prognostic Gene Expression Signatures for Squamous Cell Lung Carcinoma: A Study by the SPECS Lung Consortium
Authors: Raphael Bueno, William Richards, David Beer, Karla Ballman, Ming Tsao, Frances Shepard, Daniel Merrick, Adriaan Van Bokhoven, Wilbur Franklin, Ramaswamy Govindan, Mark Watson, David R. Gandara, David Harpole, Zhengming Chen, Guoan Chen, Lucian Chirieac, Herman Chui, Carlo Genova, Mary-Beth Joshi, Ashley Kowalewski, Mark Onaitis, Christopher Rivard, Thomas Sporn, Fred R. Hirsch
Journal: Journal of Thoracic Oncology (2017)
Loss Of p53 Induces Leukemic Transformation In a Murine Model Of JAK2V617F-Induced Polycythemia Vera
Authors: Takako Tsuruta-Kishino, Keisuke Kataoka, Hiroshi Kobayashi, Junji Koya, Kensuke Narukawa, Tomohiko Sato, Mineo Kurokawa
Journal: Blood (2013)
P3.02c-059 CD70 Immune Checkpoint Ligand is Associated with Epithelial-To-Mesenchymal Transition in Non-Small Cell Lung Cancer
Authors: Sandra Ortiz-Cuaran, Aurélie Swalduz, Jean-Philippe Foy, Maria-Alexandra Albaret, Anne-Pierre Morel, Solène Marteau, Frédérique Fauvet, Geneviève De Souza, Christine Ménétrier-Caux, Arnaud Paré, Fanny Bouquet, Ariel Savina, Maurice Pérol, Sylvie Lantuejoul, Christophe Caux, Alain Puisieux, Pierre Saintigny
Journal: Journal of Thoracic Oncology (2017)
Deferasirox (Exjade®) Treatment in Pediatric β-Thalassemia Patients with High Iron Burden: 2.8 Years Results from ESCALATOR Trial
Authors: Ali Taher, Abdullah Al Jefri, Mohsen Saleh Elalfy, Kusai Al Zir, Shahina Daar, Ghazi Damanhouri, Ulrike Kriemler-Krahn, Dany Habr, Abdel Hmissi, Amal El-Beshlawy
Journal: Blood (2008)
Oxidized Phospholipids on Apolipoprotein B-100 and Recurrent Ischemic Events Following Stroke or Transient Ischemic Attack
Authors: Young Sup Byun, Xiaohong Yang, Weihang Bao, David DeMicco, Rachel Laskey, Joseph L. Witztum, Sotirios Tsimikas
Journal: Journal of the American College of Cardiology (2017)
A framework for analysis of linear ultrasound videos to detect fetal presentation and heartbeat
Authors: M.A. Maraci, C.P. Bridge, R. Napolitano, A. Papageorghiou, J.A. Noble
Journal: Medical Image Analysis (2017)

Confirmation of pregnancy viability (presence of fetal cardiac activity) and diagnosis of fetal presentation (head or buttock in the maternal pelvis) are the first essential components of ultrasound assessment in obstetrics. The former is useful in assessing the presence of an on-going pregnancy and the latter is essential for labour management. We propose an automated framework for detection of fetal presentation and heartbeat from a predefined free-hand ultrasound sweep of the maternal abdomen. Our method exploits the presence of key anatomical sonographic image patterns in carefully designed scanning protocols to develop, for the first time, an automated framework allowing novice sonographers to detect fetal breech presentation and heartbeat from an ultrasound sweep. The framework consists of a classification regime for a frame by frame categorization of each 2D slice of the video. The classification scores are then regularized through a conditional random field model, taking into account the temporal relationship between the video frames. Subsequently, if consecutive frames of the fetal heart are detected, a kernelized linear dynamical model is used to identify whether a heartbeat can be detected in the sequence. In a dataset of 323 predefined free-hand videos, covering the mother's abdomen in a straight sweep, the fetal skull, abdomen, and heart were detected with a mean classification accuracy of 83.4%. Furthermore, for the detection of the heartbeat an overall classification accuracy of 93.1% was achieved.
Apo-Transferrin Injections Reduce Transferrin Receptor 1 Concentration on Erythroid Precursors and Reverse Ineffective Erythropoiesis In Splenectomized Beta-Thalassemic Mice
Authors: Huihui Li, Jing Liu, Jianhua Zhang, Maya Shvartsman, Charles B Hall, William Breuer, Leni vonBonsdorff, Zvi Ioav Cabantchik, Xiuli An, Mohandas Narla, Yelena Ginzburg
Journal: Blood (2010)
Infectious Complications in Asian Patients Treated with Alemtuzumab: Results From a Multicenter Study.
Authors: Seok Jin Kim, Ary Harryanto Reksodiputro, Ann-Lii Cheng, Tanin Intragumtornchai, Surapol Issaragrisil, Joon Ho Moon, Jin Seok Kim, Je-Jung Lee, Jong Ho Won, Won Seog Kim, Yok Lam Kwong
Journal: Blood (2009)
Phase I Study Of P-Glycoprotein (P-gp) Mediated Drug Interactions Between Lenalidomide (LEN) and Quinidine Or Temsirolimus
Authors: Nianhang Chen, Daniel Weiss, Josephine Reyes, Liangang Liu, Claudia Kasserra, Xiaomin Wang, Simon Zhou, Gondi Kumar, Lilia Weiss, Maria Palmisano
Journal: Blood (2013)
P1.02-081 The Relationship of CDH3 Expression and DNA Methylation in Thymic Epitherial Tumors
Authors: Koichiro Kajiura, Kazuya Kondo, Toru Sawada, Naoya Kawakita, Mitsuhiro Tsuboi, Hiromitsu Takizawa, Akira Tangoku
Journal: Journal of Thoracic Oncology (2017)
Polymeric immunoglobulin receptor promotes tumor growth in hepatocellular carcinoma
Authors: Xihua Yue, Jing Ai, Yang Xu, Yi Chen, Min Huang, Xinying Yang, Bo Hu, Haotian Zhang, Changxi He, Xinrong Yang, Weiguo Tang, Xia Peng, Liwei Dong, Hongyang Wang, Jia Fan, Jian Ding, Meiyu Geng
Journal: Hepatology (2017)

Deregulation of the immune system is believed to contribute to cancer malignancy, which has led to recent therapeutic breakthroughs facilitating antitumor immunity. In a malignant setting, immunoglobulin receptors, which are fundamental components of the human immune system, fulfill paradoxical roles in cancer pathogenesis. This study describes a previously unrecognized pro‐oncogenic function of polymeric immunoglobulin receptor (pIgR) in the promotion of cell transformation and proliferation. Mechanistically, pIgR overexpression is associated with YES proto‐oncogene 1, Src family tyrosine kinase (Yes) activation, which is required for pIgR‐induced oncogenic growth. Specifically, pIgR activates the Yes‐DNAX‐activating protein of 12 kDa‐spleen tyrosine kinase‐Rac1/CDC42‐MEK (extracellular signal‐regulated kinase kinase)/ERK (extracellular signal‐regulated kinase) cascade in an immunoreceptor tyrosine‐based activating motif (ITAM)‐dependent manner to promote cell transformation and tumor growth, although pIgR itself does not contain an ITAM sequence. Additionally, the combination of pIgR and phosphorylated Yes (p‐Yes) levels serves as a prognostic biomarker for hepatitis B surface antigen–positive and early‐stage hepatocellular carcinoma (HCC) patients. Moreover, pharmacological targeting of MEK/ERK or Yes represents a therapeutic option for the subgroup of patients with pIgR/p‐Yes–positive HCC based on our results with both cancer cell‐line–based xenografts and primary patient‐derived xenografts. Conclusion : Our findings reveal the molecular mechanism by which pIgR promotes cancer malignancy, suggest the clinical potential of targeting this pathway in HCC, and provide new insight into the oncogenic role of immunoglobulin receptors. (H epatology 2017;65:1948‐1962).
Impact of taxanes on weight gain during neoadjuvant chemotherapy (Ctx) for breast cancer (BC)
Authors: M. E. Melisko, C. A. Millerick, P. Maniar, D. Moore, M. Rosenwein, H. S. Rugo, L. Esserman
Journal: Journal of Clinical Oncology (2006)

10606 Background: Weight gain after the diagnosis of BC has been associated with increased risk of recurrence and mortality. Previous studies have documented weight gain after cyclophosphamide, methotrexate, and 5-fluoruracil (CMF) and adriamycin and cyclophosphamide (AC) chemotherapy, but the impact of taxane chemotherapy has not been described. Methods: We reviewed the charts of 119 patients (pts) who completed neoadjuvant Ctx between 1997–2005. Age, baseline body mass index (BMI), tumor size, nodal status, hormone receptor status, menopausal status, co-morbid illnesses and anti-depressant use were collected. Weight was recorded at each Ctx visit and at follow-up visits for two years. Results: 22 pts received AC only. 97 pts received AC followed by a taxane - 58 docetaxel (D), 39 paclitaxel (P). Median f/u time was 26.3 months. 66/119 (55%) of pts gained weight during Ctx, with a median change of + 1 pound (range -28 to +19.5 pounds) at the end of Ctx. 49/119 (41%) of pts gained weight during AC and 76/97 (78%) of pts gained weight during the taxane. Mean weight change after AC was -1.8 pounds compared to +3.2 pounds after the taxane (p &lt; 0.001). Age, baseline BMI, and menopausal status prior to Ctx did not predict weight gain. There was no difference in weight gain between pts who received D vs. P (p = 0.19). 8/22 (36%) patients who received AC alone recurred, and 13/95 (14%) who received both AC and T recurred; however this was not statistically significant (p = 0.23). Total weight change during neoadjuvant Ctx did not predict recurrence; however weight gain during the AC portion was associated with a higher risk of recurrence when adjusted for weight gain during taxane Ctx (p = 0.035, Cox regression). Each one pound gained was associated with an 11% increase in risk of recurrence. Conclusions: Weight gain is common during neoadjuvant Ctx for BC, particulary during treatment with taxanes. Further follow up is required to establish if weight gain is maintained over time and to determine the impact of weight change on BC outcomes and health. No significant financial relationships to disclose.
P3.03-047 Diagnostic Value of Secretary Leukocyte Peptide Inhibitor (SLPI) in Pleural Fluid in Malignant Pleural Mesothelioma
Authors: Nobukazu Fujimoto, Kenji Takada, Yosuke Miyamoto, Michiko Asano, Yasuko Fuchimoto, Sae Wada, Shinji Ozaki, Takumi Kishimoto
Journal: Journal of Thoracic Oncology (2017)
P1.06-007 Radical Treatment of Synchronous Oligometastatic Non-Small Cell Lung Cancer (NSCLC)
Authors: Oscar Arrieta, Rosa Luz Luna Palencia, Omar Macedo-Pérez, Feliciano Barron, José Francisco Corona Cruz, Luis Alberto Chinchilla Trigos, Monika Blake Cerda, Federico Maldonado Magos
Journal: Journal of Thoracic Oncology (2017)
P2.06-012 Phase 2 Study of Abemaciclib + Pembrolizumab in KRAS Mutation, PD-L1+, Stage IV Non-Small Cell or Squamous Cell Lung Cancer
Authors: Julien Mazieres, Sara Tolaney, Luis Paz-Ares, Jean-Louis Pujol, Tuncay Goksel, Chia-Chi Lin, Anwar Hossain, William John, Peter Kabos
Journal: Journal of Thoracic Oncology (2017)
Epigenetic Silencing of the Receptor Tyrosine Phosphatase, PTPRK, Located At the Frequently Deleted 6q22.33-q23.2 Region, Leads to Tumor Growth Via the Constitutive Activation of STAT3 in Nasal-Type NK/T-Cell Lymphoma
Authors: Yun-Wen Chen, Tianhuan Guo, Lijun Shen, Kai-Yau Wong, Wing-Yan Au, Qian Tao, Lok-Yi Wong, Cheuk-On Tang, Wai Lap Choi, Wei-Ping Liu, Gan-Di Li, Norio Shimizu, Junjiro Tsuchiyama, Florence Loong, Raymond Liang, Yok Lam Kwong, Gopesh Srivastava
Journal: Blood (2011)
P3.02c-096 Use of Nivolumab in Elderly Patients with Advanced Squamous NSCLC: Results from the Italian Expanded Access Programme (EAP)
Authors: Francesco Grossi, Lucio Crinò, Annamaria Catino, Stefania Canova, Angelo Delmonte, Andrea Ardizzoni, Marina Garassino, Simone Scagnoli, Frederico Cappuzzo, Daniele Turci, Silvia Quadrini, Paola Antonelli, Paolo Marchetti, Armando Santoro, Sabrina Giusti, Francesco Di Costanzo, Francesca Rastelli, Paolo Sandri, Lorenzo Livi, Filippo De Marinis
Journal: Journal of Thoracic Oncology (2017)
Lamin A/C regulates TGF-beta-mediated fibroblast proliferation and collagen production by allowing PP2a to dephosphorylate Rb : A novel explanation for the adverse effects of lamin A/C mutations?
Authors: W Voncken, JL Broers, R Duisters, R van Leeuvven, P van Tintelen, FC Ramaekers, YM Pinto, Jop H. van Berlo
Journal: Circulation (2004)
OA23.05 First-Line Afatinib versus Gefitinib in EGFRm+ Advanced NSCLC: Updated Overall Survival Analysis of LUX-Lung 7
Authors: Keunchil Park, Eng Huat Tan, Li Zhang, Vera Hirsh, Ken O'Byrne, Michael Boyer, James Chih-Hsin Yang, Tony Mok, Ki Hyeong Lee, Shun Lu, Yuankai Shi, Sang-We Kim, Janessa Laskin, Dong-Wan Kim, Scott Laurie, Karl Kölbeck, Jean Fan, Nigel Dodd, Angela Märten, Luis Paz-Ares
Journal: Journal of Thoracic Oncology (2017)
Podoplanin expression in primary brain tumors induces platelet aggregation and increases risk of venous thromboembolism
Authors: Julia Riedl, Matthias Preusser, Pegah Mir Seyed Nazari, Florian Posch, Simon Panzer, Christine Marosi, Peter Birner, Johannes Thaler, Christine Brostjan, Daniela Lötsch, Walter Berger, Johannes A. Hainfellner, Ingrid Pabinger, Cihan Ay
Journal: Blood (2017)
Bcr-Abl-Independent Activation of Src Kinases Associated with Development of Dasatinib Resistance in a CML Patient.
Authors: Jitka Veselovska, Renata Solna, Marie Jarosova, Edgar Faber, Helena Urbankova, Milena Holzerova, Jana Balcarkova, Karel Indrak, Vladimir Divoky
Journal: Blood (2008)
Inflammatory genetic factors to predict restenosis in diabetic patients after percurtaneous coronary intervention
Authors: PS Monraats, AH Zwinderman, WR Agema, MP de Maat, RJ de Winter, RA Tio, PA Doevendans, J Waltenberger, E Atsma, A van der Laarse, E Van der Wal, JW Jukema
Journal: Circulation (2004)
P3.07-011 Geographical Variation in the Use of Radiotherapy and Surgical Resection for Treatment of Non-Small Cell Lung Cancer in England
Authors: Daniela Tataru, Katie Spencer, Ruth Jack, Andrew Bates, Andrzej Wieczorek, Michael Lind, Margreet Lüchtenborg Lüchtenborg
Journal: Journal of Thoracic Oncology (2017)
Locum pay rates have risen despite hourly rate cap
Authors: Abi Rimmer
Journal: BMJ (2017)

Average hourly pay rates for locums employed by NHS trusts in England rose in 2016 despite the introduction of a locum pay cap, data show.

Liaison, a company that manages staff payment systems, gathered data on the locum pay and agency commission rates paid by 60 NHS trusts between July and September 2016.1

The company found that, combined, the average hourly pay and commission rates for locums increased by £0.91 compared with the first quarter of the year (April to June), increasing the average …
P3.02b-123 Lysimachia Capillipes Capilliposide Inhibits AKT Activation and Restores Sensitivity to Gefitinib in NSCLC with Acquired Gefitinib Resistance
Authors: Shirong Zhang, Yasi Xu, Er Jin, Lucheng Zhu, Bing Xia, Xufeng Chen, Shenglin Ma
Journal: Journal of Thoracic Oncology (2017)
P141 2-year follow-up of COPD patients in the non-interventional ‘real-life’ daccord study in germany
Authors: H Worth, R Buhl, CP Criée, P Kardos, C Mailänder, N Lossi, C Vogelmeier
Journal: Thorax (2016)

<h3>Introduction</h3> Although randomised, controlled trials are important in the development of new pharmacological treatments, they provide limited information on the ‘real life’ management of chronic diseases. Here, we analysed two-year follow-up data from the prospective, non-interventional, observational DACCORD study to evaluate the frequency of exacerbations and the evolution of disease severity using GOLD 2011 categorization. <h3>Methods</h3> COPD out-patients were recruited into DACCORD following either a change or initiation of COPD maintenance medication and followed up for 2 years. Data of 3137 patients that completed the 2-year follow-up were analysed; Exacerbation data were collected from the 6 months prior to study entry (baseline), and every 3 months for 2 years after entry; COPD symptoms were evaluated using the COPD Assessment Test (CAT) at baseline as well as the 1 year and 2 year visit. <h3>Results</h3> In this cohort the non-exacerbating phenotype was stable with a total of 69.4% of patients without exacerbations in the 6 months prior to baseline not reporting any exacerbation over the full 2 year follow-up period resulting in an annual exacerbation rate of 0.263 in year 1 and 0.251 in year 2. In contrast, patients with at least one exacerbations in the 6 months prior to baseline showed an annual exacerbation rate of 0.770 in year 1 and 0.633 in year 2. At baseline 44.6% of patients were categorised as GOLD D, one third of these due to their exacerbation history alone. In Year 1 there was a general shift to lower risk categories compared to baseline (GOLD D: 44.6% vs. 31.1%) mainly due to a lower number of exacerbations in Year 1. Overall, categorization then remained relatively stable from Year 1 (GOLD D = 31.1%) to Year 2 (GOLD D = 32.1%). <h3>Conclusions</h3> Although, COPD is generally considered to be a progressive disease, this analysis of ‘real life’ data over an observational period of 2 years shows that the ‘non-*exacerbating’ phenotype is relatively stable. The data furthermore confirms that exacerbations in the recent history increase the risk of future exacerbations.
P2.03b-034 Clinical Relevant Oncogenic Drivers in Advanced Adenocarcinoma Discloses New Therapeutic Targets in Negative EGFR/ALK/KRAS Patients
Authors: Juliana Machado, Daniel Ascheri, Patrícia Leao, Priscila Milsoni, Rogerio Oliveira, Edwin Parra, Vanessa Sá, Cecília Farhat, Claudia Rainho, Alexandre Ab'saber, Maria Nagai, Teresa Takagaki, Alexandre Fabro, Vera Capelozzi
Journal: Journal of Thoracic Oncology (2017)
P161 Unmet needs in the treatment of idiopathic pulmonary fibrosis (IPF) – insights from patient chart review in five european countries
Authors: TM Maher, M Molina-Molina, A-M Russell, F Bonella, S Jouneau, E Ripamonti, J Axmann, C Vancheri
Journal: Thorax (2016)

<h3>Introduction and objectives</h3> Two antifibrotic drugs, pirfenidone and nintedanib, are approved by the FDA and EMA for the treatment of IPF. We investigated treatment patterns of European patients with IPF to understand antifibrotic treatment uptake and identify unmet needs in IPF treatment practice. <h3>Methods</h3> Between February and March 2016, respiratory physicians from France, Germany, Italy, Spain and the UK participated in an online questionnaire designed to collect information on IPF treatment patterns. Responses were collected from physicians who had consulted with ≥6 (France, Italy, Spain) or ≥10 (Germany, UK) patients with IPF (within 3 months). Patients were categorised as being in the treated population (those who had received approved antifibrotics) or the untreated population (those who had not received approved antifibrotics, but may have received other therapies). Classification of IPF diagnosis (confirmed/suspected) and severity (mild/moderate/severe) for each patient was based on the individual physician's report. <h3>Results</h3> Overall, there were 290 respondent physicians reporting on 1838 patients. Of 1783 patients with data, 54% were not treated with an approved antifibrotic. Of patients with a confirmed IPF diagnosis, 41% were not treated. In the 1737 patients analysed, the untreated population was older than the treated population (70 versus 67 years, respectively; p ≤ 0.01) and had less frequent multidisciplinary team (MDT) evaluation (57% versus 83%, respectively; p ≤ 0.01). At diagnosis, mild, moderate and severe IPF was reported in 43%, 40% and 16% of untreated patients, and 26%, 64% and 10% of treated patients, respectively. Average forced vital capacity (FVC) at diagnosis and last check-up was significantly higher in untreated patients versus treated patients (both p ≤ 0.01; Table); however, fewer untreated patients had an FVC measurement at their most recent check-up compared with treated patients (12% versus 26%, respectively; p ≤ 0.01). <h3>Conclusions</h3> Despite recent regulatory approval of antifibrotic therapies, many European patients with confirmed IPF do not receive approved antifibrotic treatment. Possible explanations may include: lack of MDT diagnosis; lack of referral to specialist centres; patients not meeting treatment thresholds; subjective perceptions of disease severity; reluctance to treat patients with 'stable' disease; variations in patient/physician awareness or knowledge of IPF; or lack of confidence in prescribing new treatments.
P2.04-018 Comprehensive Copy Number Alteration and Gene Expression Analysis of Surgically Resected Thymic Carcinoma
Authors: Takao Nakanishi, Toshi Menju, Ryo Miyata, Shigeto Nishikawa, Koji Takahashi, Hiroyuki Cho, Shinya Neri, Masatsugu Hamaji, Hideki Motoyama, Kyoko Hijiya, Toyofumi Chen-Yoshikawa, Akihiro Aoyama, Toshihiko Sato, Makoto Sonobe, Akihiko Yoshizawa, Hironori Haga, Hiroshi Date
Journal: Journal of Thoracic Oncology (2017)
Critical Role for CCR1:CCL5 (RANTES) Receptor Ligand Interactions in Modulating Allogeneic T Cell Responses Following Bone Marrow Transplantation.
Authors: Sung Won Choi, Gerhard C. Hildebrandt, Ines Silva, Krystyna M. Olkiewicz, Stephen W. Chensue, Chen Liu, Meghana Chaudhary, Jacki Fisher, Thomas E. Lane, Kenneth R. Cooke
Journal: Blood (2005)
Sixty seconds on . . . diet drinks
Authors: Anne Gulland
Journal: BMJ (2017)

A commentary in PLOS Medicine warns that there is scant evidence that so called diet (artificially sweetened) drinks help people lose weight and that they should not be recommended as part of a healthy diet.1

The authors say that studies show that diet drinks may trigger compensatory food intake by stimulating sweet taste receptors. They also warn of a psychological effect: consumers may …
P3.03-007 miR-137 Acts as a Tumor Suppressor via the Down-Regulation of YB-1 in Malignant Pleural Mesothelioma
Authors: Thomas Johnson, Karin Schelch, Yuen Yee Cheng, Kadir Sarun, Marissa Williams, Ruby Lin, Nico Van Zandwijk, Glen Reid
Journal: Journal of Thoracic Oncology (2017)